LENSAR Q4 EPS $(0.35) Misses $(0.22) Estimate, Sales $12.11M Beat $12.00M Estimate

3/4/24 7:02:39 AM ET

Medical/Dental Instruments

Health Care

Get the next $LNSR alert in real time by email

LENSAR (NASDAQ:LNSR) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.22) by 59.09 percent. This is a 45.83 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $12.11 million which beat the analyst consensus estimate of $12.00 million by 0.88 percent. This is a 18.31 percent increase over sales of $10.23 million the same period last year.

Get the next $LNSR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LNSR

Date	Price Target	Rating	Analyst
11/22/2021	$15.00	Buy	BTIG

More analyst ratings

$LNSR
Press Releases

Fastest customizable press release news feed in the world

LENSAR Reports Third Quarter 2024 Results and Provides Business Update
24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over third quarter 2023 and 22% Recurring revenue growth in twelve-month trailing average Worldwide procedure volumes increased 29% over third quarter of 2023 Installed system base grew 20% over third quarter of 2023 ORLANDO, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter
11/7/24 7:00:09 AM ET
$LNSR
Medical/Dental Instruments
Health Care
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 650 shares of the Company's common stock. The options were granted as of November 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $5.38 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest as
11/1/24 6:32:20 PM ET
$LNSR
Medical/Dental Instruments
Health Care
LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307 1963 (International). The conference ID is 8444582. To access the live webcast, please go t
10/31/24 7:00:55 AM ET
$LNSR
Medical/Dental Instruments
Health Care

LENSAR Reports Third Quarter 2024 Results and Provides Business Update
24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over third quarter 2023 and 22% Recurring revenue growth in twelve-month trailing average Worldwide procedure volumes increased 29% over third quarter of 2023 Installed system base grew 20% over third quarter of 2023 ORLANDO, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter
11/7/24 7:00:09 AM ET
$LNSR
Medical/Dental Instruments
Health Care
LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307 1963 (International). The conference ID is 8444582. To access the live webcast, please go t
10/31/24 7:00:55 AM ET
$LNSR
Medical/Dental Instruments
Health Care
LENSAR Reports Second Quarter 2024 Results and Provides Business Update
17 New ALLY® Adaptive Cataract Treatment Systems placed in 2Q 2024; highest number of placements since launch Received Medical Device Regulation (MDR) certification (CE Mark) and Taiwan FDA approval granted for commercial distribution of ALLY; First EU and Southeast Asia systems shipped Continued robust worldwide procedure growth; 2Q 2024 procedure volumes increased 19% over 2Q 2023 Installed system base grew 16% over 2Q 2023 LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2024 and provided an update on key
8/8/24 7:00:00 AM ET
$LNSR
Medical/Dental Instruments
Health Care

LENSAR Q4 EPS $(0.35) Misses $(0.22) Estimate, Sales $12.11M Beat $12.00M Estimate

Chat with this insight

Recent Analyst Ratings for $LNSR

$LNSR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BTIG initiated coverage on LENSAR with a new price target

SVB Leerink initiated coverage on LENSAR with a new price target

SVB Leerink initiated coverage on LENSAR with a new price target

$LNSR Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

$LNSR SEC Filings

SEC Form 10-Q filed by LENSAR Inc.

LENSAR Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by LENSAR Inc.

$LNSR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

$LNSR Market Insights

Live Market Insights

LENSAR Q1 2024 GAAP EPS $(0.19) Beats $(0.28) Estimate, Sales $10.588M Beat $10.550M Estimate

Lake Street Initiates Coverage On LENSAR with Buy Rating, Announces Price Target of $8